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Abstract 
Background: The renin-angiotensin-aldosterone system (RAAS) contributes to pulmonary 
hypertension (PH) pathogenesis. While animal data suggest RAAS inhibition attenuates PH, it is 
unknown if RAAS inhibition is beneficial in PH patients.  
Research question: Is RAAS inhibitor use associated with lower mortality in a large cohort of 
patients with hemodynamically confirmed PH? 
Study design and methods: We used the Department of Veterans Affairs Clinical Assessment 
Reporting and Tracking Database to retrospectively study relationships between RAAS 
inhibitors (angiotensin converting enzyme inhibitors [ACEIs], angiotensin receptor blockers 
[ARBs] and aldosterone antagonists [AAs]) and mortality in 24,221 patients with 
hemodynamically confirmed PH. We evaluated relationships in the full and in propensity-
matched cohorts. Analyses were adjusted for demographics, socioeconomic status, 
comorbidities, disease severity and co-medication use in staged models.  
Results: ACEI/ARB use was associated with improved survival in unadjusted Kaplan-Meier 
survival analyses in the full cohort and the propensity-matched cohort. This relationship was 
insensitive to adjustment, independent of pulmonary artery wedge pressure and also observed 
in a cohort restricted to individuals with pre-capillary PH. AA use was associated with worse 
survival in unadjusted Kaplan-Meier survival analyses in the full cohort; however, AA use was 
less robustly associated with mortality in the propensity-matched cohort and not associated with 
worse survival after adjustment for disease severity, indicating that that AAs in real-world 
practice are preferentially used in sicker patients and that the unadjusted association with 
increased mortality may be an artifice of confounding by indication of severity.  
Interpretation: ACEI/ARB use is associated with lower mortality in veterans with PH. AA use is a 
marker of disease severity in PH. ACEIs/ARBs may represent a novel treatment strategy for 




Pulmonary hypertension (PH) is a common complication of cardiopulmonary and 
systemic disorders1. Irrespective of the underlying etiology, PH leads to right ventricular (RV) 
failure and predicts or mediates poor outcomes1-4. Pulmonary vasodilator therapy is available for 
the relatively small subgroup of patients with pulmonary arterial hypertension (PAH; Group 1 
PH), but no specific therapies are available for the large group of patients with PH and 
increased RV afterload due to chronic heart disease, chronic lung disease or sleep-disordered 
breathing (Group 2 and 3 PH, respectively)3,4. Unfortunately, even with use of disease-specific 
therapies in PAH, 3-year survival is only 55%5. Survival in Group 2 and 3 PH is similar or even 
lower6. There is an unmet need for novel, disease-modifying treatments for PAH as well as for 
Group 2 and 3 PH7,8. 
Renin-angiotensin-aldosterone system (RAAS) inhibition is a widely accepted treatment 
for heart failure with reduced ejection fraction and systemic hypertension that exerts protective 
effects on the systemic vasculature and on myocardial remodeling9,10. Neurohormonal 
imbalance with increased RAAS activation is also a disease marker and potential treatment 
target in the RV and pulmonary vasculature in PAH11-14. Experimental and clinical studies 
suggest that RAAS inhibition may prevent PAH development and attenuate severity15-23. Given 
the benefit of RAAS inhibitors on left ventricular function and remodeling9, their use may also 
benefit the RV. This is clinically relevant, since RV function determines survival in PAH and 
because no RV-specific therapies currently exist24-26. Importantly, RV failure is the final common 
disease pathway not just in PAH, but also in all other forms of PH. RV-targeted therapy 
therefore could be beneficial across the entire spectrum of PH, which is distinct from pulmonary 
vascular targeted therapy that is helpful in PAH but may be harmful in other forms of PH27-32. 
Evidence of RAAS activation also exists in non-PAH PH. For example, increased circulating 
plasma aldosterone has been reported in patients with Group 2 PH33 and in patients with 
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advanced chronic obstructive lung disease and cor pulmonale34,35, and evidence of increased 
RAAS signaling exists in patients with pulmonary fibrosis36. 
We used the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) 
cohort (the single largest database on hemodynamically confirmed PH) to study relationships 
between RAAS inhibitors (angiotensin converting enzyme inhibitors [ACEIs], angiotensin 
receptor blockers [ARBs] and aldosterone antagonists [AA]) and mortality in a large cohort of 
patients with pre- and post-capillary forms of PH. Since the majority of patients in this cohort 
represent non-PAH PH37, CART represents a unique opportunity to study the association of 
RAAS inhibitors with clinical outcomes in individuals with common and clinically highly relevant 
types of PH. We hypothesized that ACEI/ARB and AA use would be associated with improved 
outcomes in a population with a variety of types of PH.  
Methods 
See online supplement for detailed methods. 
Participants 
The CART cohort consists of a large, national data collection of veterans who received a 
heart catheterization at a VA medical center since 200537,38. For this retrospective analysis, we 
included all veterans who received a right heart catheterization (RHC) between 2008 and 2016, 
had a mean pulmonary artery pressure (mPAP) of ≥25 mmHg (which defined PH during the 
study period), and a recorded value for pulmonary artery wedge pressure (PAWP).  
Medications 
Medication use was ascertained using the VA medical record. Participants were 
considered to have “used” a medication if an outpatient prescription was filled within 90 days of 
their RHC. Participants were excluded if they died within 90 days of their RHC or had a hospital 
stay lasting >60 days following that catheterization. The latter provided a minimum of 30 days to 
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detect outpatient medication use. RAAS inhibitor (ACEI/ARB or AA) use was the primary 
exposure in all analyses. Other baseline medications were considered as potential confounders 
(see e-Table 1 for full medication list).  
 
Covariates 
We accounted for possible non-pharmacological characteristics that might confound the 
relationship between RAAS inhibitor use and mortality. Specifically, we accounted for (1) 
demographic characteristics (age [modeled continuously], sex, race/ethnicity, and body mass 
index); (2) markers of socioeconomic status and health behaviors (current or previous history of 
smoking, current or previous history of alcohol abuse, income, marital status); (3) comorbid 
medical conditions; and (4) co-medication use (described in e-Table 1).  
 
Outcomes 
 The primary outcome was the rate of all-cause mortality. Risk time accrued after the 90-
day window that was used to establish exposure status. Separation of exposure ascertainment 
and outcome assessment was used to avoid immortal time bias and ensure all participants had 
an equal chance for exposure to ACEIs/ARBs or AAs. Mortality was determined using the 




Patient characteristics were compared by RAAS inhibitor use. We used the Kaplan & 
Meier method to estimate unadjusted associations and Cox proportional hazards regression 
using a complete case analysis to estimate adjusted associations of RAAS inhibitor use within 
90 days of RHC and mortality. A series of planned a priori adjustments were performed and 
consistent with our previous manuscripts40. In the limited model, we adjusted for age, sex, race, 
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and body mass index. In the adjusted model, we also accounted for participants’ markers of 
socioeconomic status and health behaviors.  
In separate models, we further adjusted for comorbid medical conditions or co-medication 
use. We did not specifically adjust for systemic hypertension since the adjustment for co-
medication use addressed confounding by hypertension via inclusion of antihypertensives. 
Analyses were repeated in a cohort of propensity-matched participants where subjects were 
matched according to their propensity for RAAS inhibitor prescription (see online supplement for 
further details on propensity-matching). 
In pre-specified exploratory analyses, PAWP ≤15 mmHg versus >15 mmHg was 
evaluated as an effect modifier in the association between RAAS inhibitor use and mortality. 
Given the unexpected finding suggesting worse mortality in unadjusted relationships with AA 
users relative to non-users and the decreased effect size with inconsistent statistical 
significances in the propensity-matched cohort, we considered additional exploratory 
adjustments to better understand the potential role of confounding in this relationship. In 
particular, we explored whether further adjustment by blood potassium level or markers of 
disease severity modified the relationships between AA use and mortality as well as ACEI/ARB 
use and mortality. B-type natriuretic peptide (BNP) levels and inpatient status at the time of 
RHC were used as markers of disease severity. Analyses were performed using SAS 9.4 and R 




The final cohort included 24,221 patients (Table 1). Mean age was 66.8 years. Mean 
follow-up was 3.6 ± 2.5 years and total follow-up was 86,632 person-years. Those who used 
RAAS inhibitors tended to qualitatively differ from non-medication users and tended to be 
slightly younger, non-white, heavier, and with a greater burden of comorbidities. In particular, 
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AA users appeared to have a higher prevalence of cirrhosis and alcohol use. AA users also 
appeared more likely to be inpatients at the time of RHC and had lower cardiac indices. e-Table 
2 details the medication inventory. We identified 14,912 subjects with a filled prescription for 
ACEI/ARB (Figure 1 & Table 1). Of these ACEI/ARB users, 7,480 were matched with 7,480 
non-users who were otherwise similar in their propensity to have used these medications 
(Figure 1 & e-Table 3). 4,092 subjects had a prescription for AAs filled (Figure 1 & Table 1). Of 
these, 3,936 AA users were matched to 3,936 non-users with an otherwise similar propensity to 
use AAs (Figure 1 & e-Table 4).  
 
ACEI/ARB use is associated with decreased mortality in veterans with PH 
6,141 veterans who used ACEIs/ARBs died over 56,358 person-years (10.9 deaths per 
100-person years) and 4,273 veterans who did not use ACEIs/ARBs died over 30,273 person-
years (14.1 deaths per 100 person-years). ACEI/ARB use was associated with improved 
survival in unadjusted Kaplan-Meier survival analyses in the full and propensity-matched 
cohorts (Figure 2). ACEI/ARB use was associated with a highly significant 18-20% reduction in 
the hazard of mortality in a series of consistent Cox proportional hazard models that were not 
dependent on demographics, health behaviors, co-morbidities and co-medication use (Table 2). 
Similar effect sizes and statistical differences were observed in the propensity-matched cohort 
(Table 2). The ACEI/ARB-mortality relationship was unaltered when accounting for plasma 
potassium levels or when accounting for BNP and inpatient status at the time of RHC (Table 3), 
suggesting that potassium levels or disease severity were not confounding the relationship 
between ACEI/ARB use and decreased mortality. Furthermore, PAWP greater or less than 15 
mmHg did not modify the relationship between ACEI/ARB use and mortality (all p-values for the 
interaction >0.05; e-table 5), suggesting the association with decreased mortality was not 
limited to individuals with left heart disease.  
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ACEI/ARB use is associated with decreased mortality in veterans with pre-capillary PH 
ACEI/ARB use was also associated with improved mortality in a smaller cohort of 
participants with pre-capillary PH (see e-table 6 for characteristics). In 2,875 participants with 
mPAP ≥25 mmHg, PAWP ≤15 mmHg, and PVR >3 Wood units, the hazard of mortality with 
ACEI/ARB use was 23-26% less than in non-users (HR in the model with limited 
adjustment=0.77, 95% confidence interval 0.69-0.85, p<0.001; HR in the model with full 
adjustment and accounting for comorbidity=0.74, 95% confidence interval 0.66-0.82, p<0.001).   
AA use is associated with worse survival in unadjusted Kaplan-Meier survival analyses in the 
full cohort, but only inconsistently associated with mortality the propensity-matched cohort 
1,830 veterans who used AAs died over 13,980 person-years (13.1 deaths per 100-
person years) and 8,584 veterans who did not use AAs died over 72,651 person-years (11.8 
deaths per 100 person-years). AA use was associated with worse survival in unadjusted 
Kaplan-Meier survival analyses (Figure 3). Although statistically significant, the association 
between AA use and mortality was impacted by adjustment and varied between a 9-24% 
increased risk for mortality depending on the model (Table 2). This relationship was weakest in 
the model accounting for comorbidities. PAWP did not modify the relationship between AA use 
and increased mortality (all p-values for the interaction >0.05 when evaluated in limited and fully 
adjusted models; e-table 5).  
 The association further weakened in the propensity-matched cohort. In unadjusted or 
adjusted analyses of the propensity-matched cohort, there was only a 6-8% increased risk for 
mortality with AA use, and statistical significances were markedly attenuated and not 
consistently achieved (Table 2). This raises the possibility that the association between AA use 
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and mortality in the full cohort may be confounded by the propensity of use AAs and, as such, 
may be confounded by indication and/or disease severity. 
 
AA-mortality association is insensitive to adjustment for potassium levels, but is sensitive to 
adjustment for disease severity 
Since an increase in hyperkalemia-associated morbidity and mortality was noted after 
publication of the Randomized Aldactone Evaluation Study (RALES)41, we explored pre-
procedural potassium levels as a potential confounder in a non-planned analysis after finding 
increased mortality among AA users. We found that the association between AA use and 
mortality was independent of potassium levels (Table 3). Finally, given the wide range of effect 
estimates and sensitivity to adjustment, we remained concerned there might be differences in 
disease severity between those who did and did not use AAs. Indeed, accounting for BNP and 
inpatient status at the time of RHC markedly attenuated the association between AA use and 
increased mortality in the full cohort (Table 3). This supports the hypothesis that residual 
confounding related to disease severity was present in the full model and may have accounted 
for the relationship between AA use and increased mortality.  
 
AA use does not affect mortality in veterans with pre-capillary PH 
To investigate effects of AA use on mortality in veterans with pre-capillary PH, we 
restricted our analyses to participants who used AA and had a mPAP ≥25 mmHg, PAWP ≤15 
mmHg, and PVR >3 Wood units. Both log of BNP level and inpatient status were included as 
predictors. The low number of deaths as well as exclusion of patients due to missing BNP 
values precluded confident analysis in this small cohort, and only a model with limited 
adjustment could be fit. In 529 participants with pre-capillary PH and a measurement for BNP 
(e-table 7), AA use was not associated with an effect on mortality (HR 0.98, 95% confidence 






Our data are the first to evaluate the association between RAAS inhibitors and clinical 
outcomes in a large cohort of PH patients. We demonstrate that use of ACEIs/ARBs associates 
with decreased mortality. We observed a relationship between AA use and increased mortality 
that was no longer present when more robustly accounting for possible differences in disease 
severity between AA users and non-users. 
 Approximately 70 million patients in the US are estimated to have PH and/or RV 
dysfunction42-47. PH is a particular problem veterans, where it is common and associated with 
poor outcomes, yet frequently under-recognized37,48. In veterans, even mild increases in PA 
pressures are associated with increased morbidity and mortality37. Furthermore, PH in veterans 
is not only under-recognized, but also inappropriately treated32,48. This is important since 
inappropriate treatment of non-PAH forms of PH with PAH-specific drugs is associated with 
worse outcomes27-32. One factor driving the use of PAH-specific therapy in patients without PAH 
may be the lack of treatment options for non-PAH forms of PH. Novel therapeutic strategies for 
these patients are needed. 
The large patient volume in the VA, high prevalence of chronic cardiopulmonary 
diseases and tracking of hemodynamic data through CART provide a unique opportunity to 
evaluate effects of pharmacologic interventions on outcomes in common PH phenotypes in a 
“real world” scenario. For example, we recently showed that use of H2-receptor antagonists in 
veterans with PH is associated with decreased mortality40. Survival in this cohort with relatively 
advanced age and multi-morbidity was relatively well preserved and maybe even better than 
expected for this population. This may reflect the observation that the VA system performs 
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similarly or better than the non-VA system on most of the nationally recognized measures of 
inpatient and outpatient care quality49. 
We demonstrate several findings that may contribute to understanding novel treatment 
strategies for PH. First, we show that ACEI/ARB use associates with decreased risk for 
mortality. This relationship is highly significant, relatively insensitive to adjustment and does not 
appear to depend on differences in demographics, comorbidity, co-medication-use, potassium 
levels, disease severity, or propensity to use of ACEI/ARB. Decreased mortality with ACEI/ARB 
use was also noted in the cohort with pre-capillary PH, suggesting that the benefit may not be 
simply due to appropriate treatment of left heart disease. Although confounding by indication is 
always possible in pharmaco-epidemiology, insensitivity to a wide range of adjustments and 
consistency of results in the propensity-matched cohort suggest that the association between 
ACEI/ARB use and mortality is less likely to be explained by confounding. While each of these 
approaches has limitations and opportunities for residual confounding, the strength of the 
complementary approach is in the mutual reinforcement or disagreement. In the case of 
ACEI/ARBs all approaches agreed. While not totally exculpatory, this is reassuring and adds 
scientific rigor. This differs from the AA analyses, where adjustments yielded different effect 
estimates and suggested that confounding (variably addressed by the method used) strongly 
influenced the observed relationship. In addition, the high level of statistical significance makes 
a false-positive result as a consequence of analyzing a large patient population less likely50. 
RAAS inhibitors are important treatments for left heart failure and systemic hypertension, 
and have shown promise in experimental PH and in exploratory clinical analyses in PAH 
patients9,10,15-22. Since the RAAS is also activated in Group 2 PH, in COPD with RV failure and 
other disorders associated with hypoxia and/or hypercarbia33-36, exploring the potential benefit of 
RAAS inhibitors in a population predominantly characterized by group 2 and 3 PH makes 
conceptual sense and fills an important clinical knowledge gap. Importantly, ACEIs/ARBs are 
inexpensive and have a favorable side effect profile, making them an attractive treatment option. 
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As hypothesized, we demonstrate benefit of ACEIs/ARBs in post-capillary PH. However, 
these drugs were also associated with improved survival in participants with pre-capillary PH. 
This finding is unusual for PH therapies, as treatment may improve outcomes in selected groups 
with pre-capillary PH but worsen outcomes in those with post-capillary PH3. While we could not 
differentiate between Group 1 or Group 3 PH in our cohort, the burden of comorbidities in the 
VA suggests that most patients with pre-capillary disease exhibit a Group 3 phenotype (39% of 
our patients had a diagnosis of COPD; 15% had a diagnosis of OSA). Prior studies suggest 
increased RAAS activation may contribute to RV dysfunction in lung disease34,35 and may 
mediate PAH development15. As such, the survival benefit observed in our smaller pre-capillary 
PH cohort is biologically plausible, especially since RV dysfunction is common in the CART 
population51. Future studies will need to corroborate our findings in additional well-phenotyped 
PH populations and identify mechanisms of how ACEIs/ARBs exert their potential protective 
effects. Such studies should also answer the important question if protective ACEI/ARB effects 
target the RV, the pulmonary vasculature, both, or perhaps other organ systems. Such studies 
will need to address whether benefits of ACEIs/ARBs extend to both Group 1 and Group 3 PH 
or are limited to one of these groups. Studies manipulating angiotensin signaling in PAH 
patients are currently ongoing (NCT01181284, NCT01884051). Our data suggest that additional 
studies evaluating ACEI/ARB use in Group 3 PH may be warranted. 
We found an unexpected association between AA use and increased mortality in the full 
cohort. However, in counter-point to the findings with ACEI/ARB use, this association exhibited 
a less robust level of statistical significance50, was variable, and only inconsistently observed in 
the propensity-matched cohort. Furthermore, this association was sensitive to adjustment for 
disease severity. This suggests that residual confounding related to disease severity was likely 
present in full and unadjusted models using the full cohort. In CART, AA use in veterans with 
PH appears to be a marker of disease severity rather than a mediator of worse survival. Our 
results suggest that sicker patients may have received AA rather than patients with milder 
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disease, which may reflect the typical clinical practice of adding therapies in patients with 
advanced or refractory symptoms. Two previous studies suggest that AA therapy is indeed 
prescribed preferentially in patients with greater pulmonary vascular disease burden. In the 
ARIES trial of ambrisentan for PAH, enrolled patients were treated with spironolactone based on 
the discretion of their personal physician19. Analysis of these patients demonstrated that 61% of 
patients were prescribed spironolactone to treat “RV failure”, “refractory edema”, or “electrolyte 
imbalances”. Each of these scenarios suggests spironolactone use to offset or mitigate end-
organ damage caused by PAH. Second, in a recent single-center cohort study, patients 
prescribed AA therapy had more severe RV contractile dysfunction, and a trend toward higher 
PAWP and more frequent loop diuretic use52. As a result, care must be taken when interpreting 
associations between AA use and mortality, and future observational studies should be 
particularly mindful of the potential for confounding by indication52.  
Our study has limitations. Unmeasured or residual confounding can complicate the 
inference in observational studies. While a number of the adjustments were intended to isolate 
RAAS inhibition from a suite of potentially causative health-focused behaviors (e.g., a “healthy-
user” paradigm), residual confounding may well persist and adjustment for health behaviors like 
exercise and diet was not possible. Confounding by indication is also common in pharmaco-
epidemiology and appears to have been a particular problem in the association with AA use. 
This reinforces the need for cautious inference53. In addition, all-cause mortality is not “cause-
specific”54. Cause-specific mortality was not available for the CART cohort and non-
cardiovascular explanations for our findings are possible. As such, we cannot determine if 
beneficial effects of ACEIs/ARBs were due to effects on the pulmonary vasculature, the RV or 
other mechanisms. While follow-up RHC data are available for a subgroup of CART subjects 
and could help answer this question, analysis of these patients outside of a controlled clinical 
trial would introduce selection bias since repeat RHCs tend to be performed in sicker patients 
with an unsatisfying treatment response. We used RAAS inhibitor exposure near the time of 
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RHC as a marker of individuals who likely had significant exposure. Documentation of one 
outpatient prescription fill may not be a robust surrogate marker for consistent RAAS use vs. 
non-use and represents a limitation of the data source. This misclassification of measured 
exposure relative to the exposure of interest is likely; however, because this non-differential 
misclassification is not conditioned on the outcome, it Is likely conservative and may bias 
observed results toward the null hypothesis. Information on cumulative doses and/or duration of 
use would have strengthened the study; however, this was not measured and relationships 
using these important biologic gradients are not available to support casual inference on our 
data. Lastly, the strong male predominance in our cohort limits generalizability. Gender 
differences in the response to spironolactone therapy have been reported55, and it is possible 
that specific effects of AAs on subgroups of patients were not captured despite rigorous 
adjusting. 
Nonetheless, this is the largest single cohort of individuals with invasively confirmed PH 
and we believe our data support ongoing study of RAAS signaling in diseases with increased 
RV afterload. In particular, the association with benefit among those using ACEIs/ARBs was 
robust in several models and cohorts and, alongside strong pre-clinical data, may justify 
randomized controlled study of ACEIs/ARBs in patients with PAH and other forms of PH. 
ACEIs/ARBs are relatively inexpensive and have a favorable side effect profile. If our results 
can be confirmed in additional cohorts and in prospective, randomized studies, ACEIs/ARBs 




We demonstrate in a large cohort of veterans with invasively confirmed PH that 
ACEI/ARB use associates with a decreased risk for mortality. This relationship is insensitive to 
adjustment and is also observed in patients with pre-capillary PH, suggesting the observed 
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benefit is not simply explained by appropriate treatment of left heart disease. AA use appears to 
be a marker of disease severity in PH. If these hypothesis-generating results can be confirmed 
in prospective, randomized clinical studies, ACEIs/ARBs may represent an attractive and novel 
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Fig. 1: Study sample. Cohorts studied included the full study cohort as well as limited cohorts 
used for propensity matched analyses. 
Fig. 2: Angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker 
(ARB) use is associated with decreased mortality in veterans with pulmonary 
hypertension. (A) Kaplan-Meier curves for the outcome of mortality for ACEI/ARB users and 
non-users for the full cohort (14,912 users; 9,309 non-users). Five-year mortality in ACEI/ARB 
users was 35.0% (5,212 events) compared to 41.2% in non-users (3,837 events). (B) Kaplan-
Meier curves for the outcome of mortality for the propensity matched cohort (7,480/group). 
ACEI/ARB use was defined as use of either medication class within 90 days of right heart 
catheterization. Group comparisons were performed by log-rank test. Chi Sq = 154.8 for (A); Chi 
sq = 65.8 for (B). 
Fig. 3: Aldosterone antagonist (AA) use is associated with increased mortality in 
veterans with pulmonary hypertension, with a less robust association in the propensity 
matched cohort. (A) Kaplan-Meier curves for the outcome of mortality for AA users and non-
users for the full cohort (4,092 users; 20,129 non-users). Five-year mortality in AA users was 
39.2% (1,606 events) compared to 37.0% in non-users (7,443 events). (B) Kaplan-Meier curves 
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for the outcome of mortality for the propensity matched cohort (3,936/group). AA use was 
defined as use within 90 days of right heart catheterization. Group comparisons were performed 
by log-rank test. Chi sq = 14.1 for (A); Chi sq = 4.5 for (B). Note lower Chi square value and less 





Table 1: Characteristics of the study cohort. Values are expressed in percent, with absolute numbers included in parentheses (with 
the exception of income, hemodynamics and BNP levels, which are expressed as means with standard deviation).  
Variable 
All subjects  
(N = 24,221) 
ACEI/ARB  
users  
(N = 14,912) 
ACEI/ARB  
non-users  
(N = 9,309) 
AA  
users  
(N = 4,092) 
AA 
non-users  
(N = 20,129) 
Age           
• <45 years 1.9 (452) 2.0 (295) 1.7 (157) 3.7 (152) 1.5 (300) 
• 45-54 years 8.1 (1968) 8.2 (1220) 8.0 (748) 11.3 (461) 7.5 (1507) 
• 55-64 years 34.2 (8287) 35.7 (5322) 31.9 (2965) 41.1 (1683) 32.8 (6604) 
• 65-74 years 35.3 (8538) 35.1 (5239) 35.4 (3299) 31.6 (1295) 36.0 (7243) 
• 75-84 years 17.0 (4116) 16.1 (2406) 18.4 (1710) 10.9 (444) 18.2 (3672) 
• ≥85 years 3.6 (860) 2.9 (430) 4.6 (430) 1.4 (57) 4.0 (803) 
Sex (male) 96.6 (23395) 97.2 (14492) 95.6 (8903) 97.1 (3972) 96.5 (19423) 
Race           
• White 76.6 (18545) 75.2 (11218) 78.7 (7327) 70.9 (2903) 77.7 (15642) 
• Black 21.3 (5165) 22.7 (3379) 19.2 (1786) 27.0 (1106) 20.2 (4059) 
• Other 2.1 (511) 2.1 (315) 2.1 (196) 2.0 (83) 2.1 (428) 
Body mass index           
• Underweight (<18.5) 0.8 (186) 0.6 (84) 1.1 (102) 0.6 (25) 0.8 (161) 
• Normal (≥18.5 - 25) 16.9 (4090) 15.8 (2353) 18.7 (1737) 16.8 (688) 16.9 (3402) 
• Overweight (≥25 - 30) 29.2 (7068) 28.5 (4253) 30.2 (2815) 29.1 (1189) 29.2 (5879) 
• Obese (≥30 - 35) 25.0 (6051) 25.3 (3766) 24.5 (2285) 24.3 (993) 25.1 (5058) 
• Severely obese (≥35) 28.2 (6826) 29.9 (4456) 25.5 (2370) 29.3 (1197) 28.0 (5629) 
Socioeconomic status           
• Tobacco use 62.1 (15048) 62.3 (9288) 61.9 (5760) 62.9 (2572) 62.0 (12476) 
• Alcohol abuse 11.1 (2687) 11.1 (1657) 11.1 (1030) 14.2 (582) 10.5 (2105) 
• Income ($/year) 49886 (17439) 49628 (17215) 50299 (17785) 49378 (16872) 49989 (17551) 
Marital status           
• Married 48.7 (11805) 48.0 (7162) 49.9 (4643) 46.4 (1900) 49.2 (9905) 
• Divorced 29.9 (7240) 30.4 (4529) 29.1 (2711) 31.7 (1298) 29.5 (5942) 
• Single 13.7 (3324) 14.3 (2132) 12.8 (1192) 15.7 (641) 13.3 (2683) 
• Widowed 7.6 (1852) 7.3 (1089) 8.2 (763) 6.2 (253) 7.9 (1599) 
Comorbidities      
• Asthma 5.4 (1315) 5.4 (807) 5.5 (508) 5.6 (230) 5.4 (1085) 
• Atrial fibrillation/flutter 34.0 (8239) 34.1 (5082) 33.9 (3157) 38.3 (1568) 33.1 (6671) 
• CHD  0.6 (146) 0.5 (81) 0.7 (65) 0.4 (17) 0.6 (129) 
• CHF 68.7 (16636) 73.4 (10947) 61.1 (5689) 90.5 (3705) 64.2 (12931) 
• Cirrhosis 7.3 (1780) 6.3 (933) 9.1 (847) 11.8 (483) 6.4 (1297) 
• CKD 35.0 (8468) 32.6 (4867) 38.7 (3601) 36.3 (1486) 34.7 (6982) 
• COPD 38.6 (9358) 36.8 (5492) 41.5 (3866) 37.8 (1546) 38.8 (7812) 
• Diabetes 52.7 (12771) 55.8 (8326) 47.7 (4445) 55.2 (2257) 52.2 (10514) 
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• Hypertension 90.6 (21944) 93.3 (13919) 86.2 (8025) 90.8 (3716) 90.6 (18228) 
• ILD 0.7 (164) 0.6 (85) 0.8 (79) 0.4 (15) 0.7 (149) 
• MI, PCI or CABG 41.7 (10103) 43.3 (6460) 39.1 (3643) 46.5 (1901) 40.7 (8202) 
• OSA 15.2 (3685) 15.3 (2280) 15.1 (1405) 17.1 (700) 14.8 (2985) 
• Valvular heart disease 39.4 (9551) 37.6 (5608) 42.4 (3943) 32.9 (1345) 40.8 (8206) 
Hemodynamics 
• RAP (mmHg) 12.1 (5.7) 12.2 (5.6) 11.9 (5.9) 13.3 (6.2) 11.8 (5.5) 
• mPAP (mmHg) 35.3 (8.5) 35.3 (8.4) 35.2 (8.7) 37.0 (8.7) 35.0 (8.5) 
• PAWP (mmHg) 21.5 (7.5) 22.1 (7.4) 20.6 (7.6) 23.6 (7.7) 21.0 (7.4) 
• CI (L/min/m2) 2.4 (0.7) 2.4 (0.7) 2.5 (0.7) 2.2 (0.7) 2.5 (0.7) 
• PVR (Wood units) 3.0 (2.1) 2.9 (1.9) 3.1 (2.3) 3.1 (2.1) 2.9 (2.1) 
• MAP (mmHg) 93.1 (10.2) 93.6 (10.5) 92.2 (9.7) 91.4 (11.3) 93.4 (10.0) 
Disease severity 
• Inpatient status 48.2 (11685) 51.5 (7680) 43.0 (4005) 67.8 (2036) 45.5 (9649) 
• BNP (pg/ml) 1,081 (2197) 1,060 (2111) 1,119 (2346) 1,334 (2665) 995 (2006) 
Definition of abbreviations: BNP = B-type natriuretic peptide, CABG = coronary artery bypass grafting, CHD = congenital heart disease, 
CHF = congestive heart failure, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ILD = interstitial lung 
disease, MI = myocardial infarction, OSA = obstructive sleep apnea, PCI = percutaneous coronary intervention; RAP = right atrial 
pressure, mPAP = mean pulmonary arterial pressure, PAWP = pulmonary artery wedge pressure, CI = cardiac index, PVR = pulmonary 














Table 2: Cox proportional hazard models for ACEI/ARB exposure and for AA exposure. Summarized are the hazard ratios of 
death (HR with 95% confidence intervals) associated with exposure to an ACEI or ARB (upper panel) or for exposure to an AA (lower 
panel). Results are presented with and without adjustment in the full cohort and the smaller cohort of participants who used RAAS 
inhibitors compared to participants with an otherwise similar propensity to use RAAS inhibitors who did not use these medications.  
                Full Cohort# Propensity-matched Cohort## 
ACEI/ARB HR: ACEI/ARB p-value HR: ACEI/ARB p-value 
Unadjusted 0.78 (0.75,0.81) <.001 0.82 (0.78,0.86) <.001 
Limited adjustment* 0.81 (0.78,0.84) <.001 0.82 (0.78,0.86) <.001 
Full adjustment† 0.81 (0.78,0.84) <.001 0.82 (0.78,0.86) <.001 
Full adjustment† + Comorbidity§  0.78 (0.75,0.81) <.001 0.80 (0.76,0.84) <.001 
Full adjustment† + Co-medication use‡ 0.80 (0.76,0.83) <.001 0.81 (0.77,0.85) <.001 
     
AA HR: AA p-value HR: AA p-value 
Unadjusted 1.11 (1.05,1.16) <.001 1.07 (1.01,1.15) 0.03 
Limited adjustment* 1.24 (1.18,1.31) <.001 1.07 (1.00,1.15) 0.04 
Full adjustment† 1.24 (1.18,1.30) <.001 1.07 (1.00,1.14) 0.05 
Full adjustment† + Comorbidity§ 1.09 (1.03,1.14) <.01 1.08 (1.01,1.15) 0.03 
Full adjustment† + Co-medication use‡ 1.16 (1.10,1.22) <.001 1.06 (0.99,1.13) 0.08 
Definition of abbreviations: ACEI = Angiotensin converting enzyme inhibitors; ARB = angiotensin receptor blockers; AA= aldosterone 
antagonists; RAAS = renin angiotensin aldosterone system; HR = hazard ratio 
* Limited adjustment accounts for age, sex, race/ethnicity, and body mass index 
† Full adjustment accounts for the limited model and income, tobacco use, alcohol abuse, and marital status 
§ Comorbidity included the presence or absence of end-stage renal disease / dialysis, diabetes mellitus, cirrhosis, sleep disordered 
breathing, chronic obstructive pulmonary disease or asthma, interstitial lung disease, prior myocardial infarction, prior percutaneous 
coronary intervention, prior coronary artery bypass graft, congestive heart failure, valvular heart disease, congenital heart disease, 
atrial fibrillation, and/or atrial flutter 
‡ Co-medication use included all non-H2RA medications included in Table E1 
// Participants in the restricted cohorts were considered in models with full adjustment 










Table 3: Exploratory Cox proportional hazard models for ACEI/ARB or AA exposure in veterans including adjustment for 
potassium level or disease severity. Fully adjusted models for entire cohort and propensity-matched cohort (from table 2) are 
included for reference. 
   Full Cohort  Propensity-matched Cohort 
ACEI/ARB HR: ACEI/ARB p-value HR: ACEI/ARB p-value
Full adjustment† 0.81 (0.78,0.84) <.001  0.82 (0.78,0.86) <.001 
Full adjustment† with further adjustment for potassium  0.80 (0.77,0.83)* <.001 0.81 (0.77,0.85)** <.001 
Full adjustment† with further adjustment for disease severity§ 0.72 (0.67,0.78)# <.001 0.77 (0.70,0.85)## <.001 
AA HR: AA p-value HR: AA p-value
Full adjustment† 1.24 (1.18,1.30) <.001  1.07 (1.00,1.14) 0.05 
Full adjustment† with further adjustment for potassium  1.23 (1.17,1.30)* <.001 1.08 (1.01,1.15)*** 0.03 
Full adjustment† with further adjustment for disease severity§ 1.05 (0.96,1.14)# 0.28 1.04 (0.93,1.16)### 0.48 
Definition of abbreviations: ACEI = Angiotensin converting enzyme inhibitors; ARB = angiotensin receptor blockers; AA = aldosterone 
antagonists; BNP = B-type natriuretic peptide; HR = hazard ratio 
† Full adjustment accounts for age, sex, race/ethnicity, body mass index income, tobacco use, alcohol abuse, and marital status 
§ Adjustment for disease severity also accounts for B-type natriuretic peptide level and inpatient admission
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